FDA Updates Digital Health Export Guidelines: New Labeling Requirements for Medical AI Pages

On July 18, 2026, the U.S. FDA released the revised Digital Health Export Guidance, further clarifying the requirements for labeling pages containing AI-generated content on medical device, IVD, and health-related independent websites targeting the U.S. market. This change deserves close attention from export companies, independent website operators, compliance review teams, and content service providers that rely on AI-generated product descriptions, indications for use, or clinical data summaries, as it directly affects compliant content presentation for the U.S. market and may also influence website launches, content review, and delivery coordination.

What page presentation requirements have been clarified in this revision?

According to the confirmed information, the U.S. FDA released the revised Digital Health Export Guidance on July 18, 2026. According to the summary, all medical device, IVD, and health-related independent websites targeting the U.S. market that use AI-generated content, including product descriptions, indications for use, and clinical data summaries, must clearly display the English statement “This content is AI-generated for informational purposes only” at the bottom of the page and link to the complete algorithm explanation document.

Based on the content provided, this requirement concerns the presentation and information disclosure methods used on relevant website pages targeting the U.S. market. The key change is that whenever page content is AI-generated, companies may no longer decide independently whether to include a notice. Instead, they must add the prescribed English statement and provide a link to the algorithm explanation document.

The change primarily affects content delivery and U.S. market presentation

Independent website operations and export marketing pages need to be adjusted together

The analysis indicates that operators of medical device, IVD, and health-related independent websites directly promoting products in the U.S. market will be affected first. This is because the rules concern page-bottom disclosures and links to algorithm explanation documents, meaning that website structure, content publishing workflows, and pre-launch review procedures must all be checked for AI-generated content. For relevant companies, the current focus is not general promotional adjustments, but whether the English notice is complete and clearly visible, and whether the algorithm explanation document link can be configured at the time of delivery.

Requirements for coordinating compliance and certification package materials are increasing

From an industry perspective, internal compliance review teams, external certification package service providers, and third-party content suppliers involved in organizing materials may also be affected. When pages include indications for use, clinical data summaries, or similar content, companies must verify before external publication which content is AI-generated, which content requires a notice, and whether the page disclosure remains consistent with the algorithm explanation document. The impact is primarily reflected in compliance review, technical documentation retention, and consistency management for external materials, rather than merely in copy revisions.

Purchasers and channel partners may strengthen preliminary checks

Purchasers, channel distributors, or platform partners working with companies targeting the U.S. market may also include these page disclosure requirements in their preliminary checks. This is not because the information provided has already resulted in a uniform market outcome, but because once a page is regarded as part of the materials presented to the U.S. market, partners often need to confirm before traffic acquisition, listing, channel promotion, or joint advertising whether the page information complies with the latest regulatory presentation requirements. Companies therefore need to monitor not only whether their own websites have been updated, but also whether external cooperation pages, landing pages, and information pages are being handled consistently.

Which operational details should companies focus on now?

First identify which content is AI-generated

The most practical first step for companies is to review which content on their independent websites was generated by AI, particularly the product descriptions, indications for use, clinical data summaries, and other sections specifically mentioned in the summary. Only after completing this content identification can subsequent page labeling, link additions, and review procedures be implemented effectively.

The page notice and algorithm explanation document must appear as a complete package

According to the confirmed facts, the English notice at the bottom of the page and the link to the complete algorithm explanation document are paired requirements. Companies need to focus not only on adding a notice, but also on whether a linkable algorithm explanation document has been prepared and whether the document corresponds to the page content. If content generation, website development, and compliance review are handled by different internal teams, delivery coordination should begin in advance.

Pre-launch review procedures may need additional checkpoints

Companies that continuously update landing pages, campaign pages, or product pages should consider adding AI content labeling to their pre-launch checklists. The current information does not provide more detailed implementation procedures, so it should not be presented as evidence that a uniform review outcome has already been established. In practice, however, whether a page contains AI-generated content, whether the notice is complete, and whether the algorithm explanation link is valid are already checkpoints worth incorporating into the process in advance.

Companies should continue monitoring whether implementation procedures are further refined

From an industry implementation perspective, companies also need to continue tracking subsequent official statements, particularly the boundaries for identifying “AI-generated content,” the presentation format for algorithm explanation documents, and whether further differentiated requirements will apply to different types of pages. Since the input does not provide more specific rules, this aspect is currently better understood as an implementation-level issue requiring continued observation.

This appears more like a shift toward earlier responsibility for page disclosures

From an editorial perspective, the significance of this information lies not simply in adding a sentence to a page, but in the fact that regulatory attention has reached the identifiability of AI-generated content presented to the U.S. market. It reflects a shift in disclosure responsibility related to information about medical devices, IVDs, and health products toward the page level. Companies should now pay closer attention to whether they have treated AI-generated content as a compliance subject requiring separate management, rather than merely as a marketing production tool.

At the same time, this change is better understood as an implementation signal that has already emerged. The reason is that the information provided specifies the subject, applicable scenarios, and the required English notice. However, the more detailed implementation procedures, industry feedback, and market-side validation methods associated with these requirements still need to be monitored. At this stage, they should not be expanded into more definitive conclusions about the market.

Compliance for external presentation is becoming more specific

Overall, the signal released by this revision of the FDA’s Digital Health Export Guidance is relatively clear: for independent website pages targeting the U.S. market that use AI-generated content and concern medical devices, IVDs, or health products, the presentation method itself has become a compliance matter requiring attention. In the short term, this change will primarily affect website content management, page delivery, and review coordination. In the medium term, it may extend to channel cooperation and consistency checks for materials.

Accordingly, it is currently more appropriate to understand this information as a rule change that has reached the level of practical operations, while continuing to monitor subsequent detailed rules and implementation feedback. It should not be interpreted more broadly as meaning that uniform outcomes have already been established for all related processes.

Basis of this article and areas for further verification

This article was generated based on the information title, event date, and event summary provided by the user. The core sources include the U.S. FDA’s update to the Digital Health Product Export Guidance, the event date of July 18, 2026, and summary information stating that pages containing AI-generated content must include an English notice and link to an algorithm explanation document.

For events of this type, continued verification is normally required against information released by regulatory authorities, official announcements, industry association updates, standards organization documents, trade and compliance notices, and reports from authoritative media. Since the input does not provide a specific official source link, the relevant original documents and subsequent explanations still need to be verified. Areas requiring continued observation include whether policy details are supplemented, whether implementation procedures are refined, whether new requirements emerge in certification and compliance reviews, whether tender or procurement documents change accordingly, and how industry feedback and company implementation evolve.